BACKGROUND AND OBJECTIVE: Most of the carcinogenic effects of polycyclic aromatic hydrocarbons present in tobacco smoke are mediated by the aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor that regulates tobacco-induced expression of carcinogen metabolic enzymes. We hypothesized that genetic variations in AHR might confer individual susceptibility to lung cancer. METHODS: Eight selected single-nucleotide polymorphisms in AHR were genotyped using the Illumina SNP genotyping BeadLab platform in a case-control study of 500 lung cancer patients and 517 cancer-free controls in a Chinese population. RESULTS: We found that significantly increased lung cancer risk was associated with heterozygous genotypes of rs2158041 (adjusted odds ratio=1.53 and 95% confidence interval=1.17-1.99 for GA, compared with the GG genotype) and rs7811989 (adjusted odds ratio=1.48 and 95% confidence interval=1.13-1.93 for GA, compared with the GG genotype), although these two single-nucleotide polymorphisms were in linkage disequilibrium. Furthermore, haplotype analysis revealed significant differences in haplotype distributions of AHR between cases and controls (Global P=1.38e-5). We also observed statistically significant interaction between the polymorphism rs2066853 (p.Arg554Lys) and cumulative cigarette smoking as a discrete or continuous variable (P=0.033 and 0.019, respectively), and the Lys/Lys genotype conferred an increased risk of lung cancer in the heavy smokers (adjusted odds ratio=3.36 and 95% confidence interval=1.07-10.55). CONCLUSION: These findings suggest that AHR polymorphisms and potential gene-smoking interaction may be involved in the etiology of lung cancer. Further large prospective studies with ethnically diverse populations and functional studies are warranted to validate these findings.
BACKGROUND AND OBJECTIVE: Most of the carcinogenic effects of polycyclic aromatic hydrocarbons present in tobacco smoke are mediated by the aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor that regulates tobacco-induced expression of carcinogen metabolic enzymes. We hypothesized that genetic variations in AHR might confer individual susceptibility to lung cancer. METHODS: Eight selected single-nucleotide polymorphisms in AHR were genotyped using the Illumina SNP genotyping BeadLab platform in a case-control study of 500 lung cancerpatients and 517 cancer-free controls in a Chinese population. RESULTS: We found that significantly increased lung cancer risk was associated with heterozygous genotypes of rs2158041 (adjusted odds ratio=1.53 and 95% confidence interval=1.17-1.99 for GA, compared with the GG genotype) and rs7811989 (adjusted odds ratio=1.48 and 95% confidence interval=1.13-1.93 for GA, compared with the GG genotype), although these two single-nucleotide polymorphisms were in linkage disequilibrium. Furthermore, haplotype analysis revealed significant differences in haplotype distributions of AHR between cases and controls (Global P=1.38e-5). We also observed statistically significant interaction between the polymorphism rs2066853 (p.Arg554Lys) and cumulative cigarette smoking as a discrete or continuous variable (P=0.033 and 0.019, respectively), and the Lys/Lys genotype conferred an increased risk of lung cancer in the heavy smokers (adjusted odds ratio=3.36 and 95% confidence interval=1.07-10.55). CONCLUSION: These findings suggest that AHR polymorphisms and potential gene-smoking interaction may be involved in the etiology of lung cancer. Further large prospective studies with ethnically diverse populations and functional studies are warranted to validate these findings.
Authors: Jonatan Axelsson; Jens Peter Bonde; Yvonne L Giwercman; Lars Rylander; Aleksander Giwercman Journal: Asian J Androl Date: 2010-03-29 Impact factor: 3.285
Authors: Barbara C Spink; Michael S Bloom; Susan Wu; Stewart Sell; Erasmus Schneider; Xinxin Ding; David C Spink Journal: Toxicol Appl Pharmacol Date: 2014-11-04 Impact factor: 4.219
Authors: Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom Journal: Anticancer Res Date: 2013-04 Impact factor: 2.480
Authors: Shepherd H Schurman; Terrance P O'Hanlon; John A McGrath; Artiom Gruzdev; Arsun Bektas; Hong Xu; Stavros Garantziotis; Darryl C Zeldin; Frederick W Miller Journal: J Autoimmun Date: 2019-11-21 Impact factor: 7.094
Authors: Maria Florencia Torti; Federico Giovannoni; Francisco Javier Quintana; Cybele Carina García Journal: Front Immunol Date: 2021-03-05 Impact factor: 7.561
Authors: Jonatan Axelsson; Lars Rylander; Anna Rignell-Hydbom; Karl Ågren Silfver; Amelie Stenqvist; Aleksander Giwercman Journal: PLoS One Date: 2013-06-26 Impact factor: 3.240